EP Patent

EP2210893A1 — Polymorphous forms of rifaximin as antibiotics

Assigned to Alfa Wasserman SpA · Expires 2010-07-28 · 16y expired

What this patent protects

Crystalline polymorphic forms of rifaximin (INN), referred to as rifaximin α and rifaximin β, and a poorly crystalline form referred to as rifaximin γ, useful in the production of medicaments containing rifaximin for the oral and topical use and obtained by means of a crystalliza…

USPTO Abstract

Crystalline polymorphic forms of rifaximin (INN), referred to as rifaximin α and rifaximin β, and a poorly crystalline form referred to as rifaximin γ, useful in the production of medicaments containing rifaximin for the oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and causing the crystallization of the product by addition of water at a fixed temperature and for a fixed period of time, followed by drying under controlled conditions until reaching a precise water content in the end product, are the object of the invention.

Drugs covered by this patent

Patent Metadata

Patent number
EP2210893A1
Jurisdiction
EP
Classification
—
Expires
2010-07-28
Drug substance claim
No
Drug product claim
No
Assignee
Alfa Wasserman SpA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.